MacroGenics
MGNX
130 hedge funds and large institutions have $789M invested in MacroGenics in 2018 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 43 increasing their positions, 42 reducing their positions, and 12 closing their positions.
25% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 12
2% more funds holding
Funds holding: 127 → 130 (+3)
2% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 42
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
1% less capital invested
Capital invested by funds: $794M → $789M (-$5M)
4.01% less ownership
Funds ownership: 91.1% → 87.1% (-4%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $212K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$7.03M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$6.26M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$5.65M |
| 4 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
+$3.74M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$25.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.97M |
| 3 |
AH
Aviva Holdings
New Providence,
Bahamas
|
-$6.66M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$6.25M |
| 5 |
State Street
Boston,
Massachusetts
|
-$5.93M |
MGNX Hedge Fund Activity: Q3 2018 in Review
130 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in MacroGenics (MGNX) for Q3 2018, worth a combined $789M — down 0.63% from $794M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new MGNX positions and 12 closed out — a net gain of 3 holders — while 43 added to existing stakes and 42 trimmed.
The largest buyer was BB Biotech, adding an estimated $7.03M. The largest seller was Boxer Capital, exiting entirely with an estimated $25.7M sold.
- 130 institutional investors held MacroGenics (MGNX) as of Q3 2018, up from 127 in Q2 2018.
- Funds reported $789M of MacroGenics stock for Q3 2018, down 0.63% quarter-over-quarter.
- 15 funds opened new MacroGenics positions in Q3 2018 and 12 closed out, a net change of +3 holders.
- The largest MacroGenics buyer in Q3 2018 was BB Biotech, an estimated $7.03M added.
- The largest MacroGenics seller in Q3 2018 was Boxer Capital, an estimated $25.7M sold.
Based on aggregated 13F filings for Q3 2018.